LumiraDx INR Test:

Evaluation of the Accuracy of the LumiraDx INR Test Using Patients in Receipt of Phenprocoumon Anticoagulation Therapy

Voller, H and Heyne, K.

Point of Care: The Journal of Near-Patient Testing & Technology. 11th, September 2020 – Volume 19 – Issue 3 – p 72 - 76

The most commonly prescribed VKA’s are Coumadin (Warfarin), Phenprocoumon (Marcumar®, Falithrom®) and Acenocoumerol and within Europe, there are country to country differences in preferential vitamin K antagonist (VKA) prescription. In Germany and surrounding countries, Phenprocoumon is the most commonly prescribed. This study assessed accuracy of the LumiraDx INR test when used in a German clinic with patients taking phenprocoumon. INR was compared with venous plasma INR measured using the IL ACL Elite Pro and Sysmex CS-5100 reference instruments.

Results were found to agree with those from the OPTIMAL study which included subjects on Coumadin (Warfarin), and demonstrated no difference in LumiraDx INR test results when patients are taking either Phenprocoumon or Coumadin as VKA therapy. The LumiraDx INR Test showed high accuracy in analyzing venous plasma and capillary whole blood from patients receiving phenprocoumon, compared to the laboratory analysers.  

The findings indicate that the LumiraDx INR Test can be used by healthcare professionals at the POC to provide reliable INR monitoring of patients who are receiving VKA therapy.

Read publication here


Supporting healthier lives, for individuals, communities and wider society.

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.

Be Informed